Cancer name Head and Neck Cancer
Cancer Type HNSC
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment Cetuximab
Drugstatus Approved
Drugbank ID DB00002
Checkpoints NA
Signature Type Protein
Signature TAP-2
Official Symbol TAP2
Mode of action PROT_R_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description Thus, investigated whether intracellular APM components were upregulated in DC incubated with cetuximab-activated NK cells plus HNC cells (JHU-029) in the presence of urelumab. Interestingly, the addition of urelumab enhanced expression of TAP-1 , TAP-2 , and LMP-2 by DC that were co-cultured with cetuximab-activated NK cells.
PMID 27496866
Title CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer